{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:17:06Z","timestamp":1791357426414,"version":"4.3.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,21]],"date-time":"2021-11-21T00:00:00Z","timestamp":1637452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,11,21]],"date-time":"2021-11-21T00:00:00Z","timestamp":1637452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40263-021-00879-w","type":"journal-article","created":{"date-parts":[[2021,11,21]],"date-time":"2021-11-21T04:27:23Z","timestamp":1637468843000},"page":"31-44","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3265-8889","authenticated-orcid":false,"given":"Frank","family":"Petzke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4470-5531","authenticated-orcid":false,"given":"Thomas","family":"T\u00f6lle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1091-3175","authenticated-orcid":false,"given":"Mary-Ann","family":"Fitzcharles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3742-729X","authenticated-orcid":false,"given":"Winfried","family":"H\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,21]]},"reference":[{"key":"879_CR1","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/j.pain.2011.06.017","volume":"152","author":"TS Jensen","year":"2011","unstructured":"Jensen TS, Baron R, Haanp\u00e4\u00e4 M, Kalso E, Loeser JD, Rice AS. A new definition of neuropathic pain. Pain. 2011;152:2204\u20135. https:\/\/doi.org\/10.1016\/j.pain.2011.06.017.","journal-title":"Pain"},{"key":"879_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.pain.2010.05.002","volume":"150","author":"C Maier","year":"2010","unstructured":"Maier C, Baron R, T\u00f6lle TR, Binder A, Birbaumer N, Birklein F, Gierthm\u00fchlen J, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain. 2010;150:439\u201350. https:\/\/doi.org\/10.1016\/j.pain.2010.05.002.","journal-title":"Pain"},{"key":"879_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neurol.2018.09.016","volume":"175","author":"D Bouhassira","year":"2019","unstructured":"Bouhassira D. Neuropathic pain: definition, assessment and epidemiology. Rev Neurol (Paris). 2019;175:16\u201325. https:\/\/doi.org\/10.1016\/j.neurol.2018.09.016.","journal-title":"Rev Neurol (Paris)."},{"key":"879_CR4","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.pain.2007.08.013","volume":"136","author":"D Bouhassira","year":"2008","unstructured":"Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136:380\u20137. https:\/\/doi.org\/10.1016\/j.pain.2007.08.013.","journal-title":"Pain"},{"key":"879_CR5","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.pain.2013.11.013","volume":"155","author":"O Van Hecke","year":"2014","unstructured":"Van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155:654\u201362. https:\/\/doi.org\/10.1016\/j.pain.2013.11.013.","journal-title":"Pain"},{"key":"879_CR6","doi-asserted-by":"publisher","first-page":"17002","DOI":"10.1038\/nrdp.2017.2","volume":"3","author":"L Colloca","year":"2017","unstructured":"Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002. https:\/\/doi.org\/10.1038\/nrdp.2017.2.","journal-title":"Nat Rev Dis Primers"},{"key":"879_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162\u201373. https:\/\/doi.org\/10.1016\/S1474-4422(14)70251-0.","journal-title":"Lancet Neurol"},{"key":"879_CR8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/ejp.1185","volume":"22","author":"MA Fitzcharles","year":"2018","unstructured":"Fitzcharles MA, Eisenberg E. Medical cannabis: a forward vision for the clinician. Eur J Pain. 2018;22:485\u201391. https:\/\/doi.org\/10.1002\/ejp.1185.","journal-title":"Eur J Pain"},{"key":"879_CR9","doi-asserted-by":"publisher","first-page":"E907","DOI":"10.1503\/cmaj.190509","volume":"19","author":"MA Fitzcharles","year":"2019","unstructured":"Fitzcharles MA, Shir Y, H\u00e4user W. Medical cannabis: strengthening evidence in the face of hype and public pressure. CMAJ. 2019;19:E907\u20138. https:\/\/doi.org\/10.1503\/cmaj.190509.","journal-title":"CMAJ"},{"key":"879_CR10","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMra1402309","volume":"370","author":"ND Volkow","year":"2014","unstructured":"Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014;370:2219\u201327. https:\/\/doi.org\/10.1056\/NEJMra1402309.","journal-title":"N Engl J Med"},{"key":"879_CR11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ejp.1118","volume":"22","author":"W H\u00e4user","year":"2018","unstructured":"H\u00e4user W, Petzke F, Fitzcharles MA. Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management: an overview of systematic reviews. Eur J Pain. 2018;22:455\u201370. https:\/\/doi.org\/10.1002\/ejp.1118.","journal-title":"Eur J Pain"},{"issue":"Suppl. 1","key":"879_CR12","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1097\/j.pain.0000000000002268","volume":"162","author":"DP Finn","year":"2021","unstructured":"Finn DP, Haroutounian S, Hohmann AG, Krane E, Soliman N, Rice ASC. Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. Pain. 2021;162(Suppl. 1):S5-25. https:\/\/doi.org\/10.1097\/j.pain.0000000000002268.","journal-title":"Pain"},{"key":"879_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2174\/187152709789824660","volume":"8","author":"J Guindon","year":"2009","unstructured":"Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord Drug Targets. 2009;8:403\u201329. https:\/\/doi.org\/10.2174\/187152709789824660.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"879_CR14","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/ejp.1297","volume":"22","author":"W H\u00e4user","year":"2018","unstructured":"H\u00e4user W, Finn DP, Kalso E, Krcevski-Skvarc N, Kress HG, Morlion B, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018;22:1547\u201364. https:\/\/doi.org\/10.1002\/ejp.1297.","journal-title":"Eur J Pain"},{"key":"879_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000766","volume":"4","author":"N Soliman","year":"2019","unstructured":"Soliman N, Hohmann AG, Haroutounian S, Wever K, Rice ASC, Finn DP. A protocol for the systematic review and meta-analysis of studies in which cannabinoids were tested for antinociceptive effects in animal models of pathological or injury-related persistent pain. Pain Rep. 2019;4: e766. https:\/\/doi.org\/10.1097\/PR9.0000000000000766.","journal-title":"Pain Rep."},{"key":"879_CR16","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/ejp.1147","volume":"22","author":"N Krcevski-Skvarc","year":"2018","unstructured":"Krcevski-Skvarc N, Wells C, H\u00e4user W. Availability and approval of cannabis-based medicines for chronic pain management and palliative\/supportive care in Europe: a survey of the status in the chapters of the European Pain Federation. Eur J Pain. 2018;22:440\u201354. https:\/\/doi.org\/10.1002\/ejp.1147.","journal-title":"Eur J Pain"},{"key":"879_CR17","unstructured":"European Medicines Agency. Epidyolex. 2019. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/epidyolex. Accessed 1 June 2020."},{"key":"879_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fpls.2016.00019","volume":"7","author":"CM Andre","year":"2016","unstructured":"Andre CM, Hausman JF, Guerriero G. Cannabis sativa: the plant of the thousand and one molecules. Front Plant Sci. 2016;7:19. https:\/\/doi.org\/10.3389\/fpls.2016.00019.","journal-title":"Front Plant Sci"},{"key":"879_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00482-020-00458-w","volume":"34","author":"L Radbruch","year":"2020","unstructured":"Radbruch L, H\u00e4user W. Cannabidiol [in German]. Schmerz. 2020;34:115\u20136. https:\/\/doi.org\/10.1007\/s00482-020-00458-w.","journal-title":"Schmerz"},{"key":"879_CR20","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/jama.2015.6358","volume":"313","author":"PF Whiting","year":"2015","unstructured":"Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313:2456\u201373. https:\/\/doi.org\/10.1001\/jama.2015.6358 (Erratum in: JAMA 2015;314:520. Erratum in: JAMA 2015;314:837. Erratum in: JAMA 2015;314:2308. Erratum in: JAMA 2016;315:1522).","journal-title":"JAMA"},{"key":"879_CR21","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/pm\/pnab050","volume":"22","author":"I Dykukha","year":"2021","unstructured":"Dykukha I, Malessa R, Essner U, \u00dcberall MA. Nabiximols in chronic neuropathic pain: a meta-analysis of randomized placebo-controlled trials. Pain Med. 2021;22:861\u201374. https:\/\/doi.org\/10.1093\/pm\/pnab050.","journal-title":"Pain Med"},{"key":"879_CR22","doi-asserted-by":"publisher","first-page":"CD012182","DOI":"10.1002\/14651858.CD012182.pub2","volume":"3","author":"M M\u00fccke","year":"2018","unstructured":"M\u00fccke M, Phillips T, Radbruch L, Petzke F, H\u00e4user W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3:CD012182. https:\/\/doi.org\/10.1002\/14651858.CD012182.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"879_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s00482-015-0089-y","volume":"30","author":"F Petzke","year":"2016","unstructured":"Petzke F, Enax-Krumova EK, H\u00e4user W. Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: a systematic review of randomized controlled studies [in German]. Schmerz. 2016;30:62\u201388. https:\/\/doi.org\/10.1007\/s00482-015-0089-y (Erratum in: Schmerz. 2017 Sep 6; PMID: 26830780).","journal-title":"Schmerz"},{"key":"879_CR24","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.jpain.2015.07.009","volume":"16","author":"MH Andreae","year":"2015","unstructured":"Andreae MH, Carter GM, Shaparin N, Suslov K, Ellis RJ, Ware MA, et al. Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data. J Pain. 2015;16:1221\u201332. https:\/\/doi.org\/10.1016\/j.jpain.2015.07.009.","journal-title":"J Pain"},{"issue":"Suppl. 1","key":"879_CR25","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1097\/j.pain.0000000000001929","volume":"162","author":"E Fisher","year":"2021","unstructured":"Fisher E, Moore RA, Fogarty AE, Finn DP, Finnerup NB, Gilron I, et al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain. 2021;162(Suppl. 1):S45-66. https:\/\/doi.org\/10.1097\/j.pain.0000000000001929.","journal-title":"Pain"},{"key":"879_CR26","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000481089","volume":"78","author":"S Schimrigk","year":"2017","unstructured":"Schimrigk S, Marziniak M, Neubauer C, Kugler EM, Werner G, Abramov-Sommariva D. Dronabinol is a safe long-term treatment option for neuropathic pain patients. Eur Neurol. 2017;78:320\u20139. https:\/\/doi.org\/10.1159\/000481089.","journal-title":"Eur Neurol"},{"key":"879_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00415-014-7502-9","volume":"262","author":"B Hoggart","year":"2015","unstructured":"Hoggart B, Ratcliffe S, Ehler E, Simpson KH, Hovorka J, Lej\u010dko J, et al. A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC\/CBD oromucosal spray in the management of neuropathic pain. J Neurol. 2015;262:27\u201340. https:\/\/doi.org\/10.1007\/s00415-014-7502-9.","journal-title":"J Neurol"},{"key":"879_CR28","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/ejp.1675","volume":"25","author":"J Aviram","year":"2021","unstructured":"Aviram J, Pud D, Gershoni T, Schiff-Keren B, Ogintz M, Vulfsons S, et al. Medical cannabis treatment for chronic pain: outcomes and prediction of response. Eur J Pain. 2021;25:359\u201374. https:\/\/doi.org\/10.1002\/ejp.1675.","journal-title":"Eur J Pain"},{"key":"879_CR29","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2147\/JPR.S192174","volume":"12","author":"MA Ueberall","year":"2019","unstructured":"Ueberall MA, Essner U, Mueller-Schwefe GH. Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry. J Pain Res. 2019;12:1577\u2013604. https:\/\/doi.org\/10.2147\/JPR.S192174.","journal-title":"J Pain Res"},{"key":"879_CR30","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1155\/2014\/754693","volume":"19","author":"D Moulin","year":"2014","unstructured":"Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, Canadian Pain Society, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19:328\u201335. https:\/\/doi.org\/10.1155\/2014\/754693.","journal-title":"Pain Res Manag"},{"key":"879_CR31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00482-019-00407-2","volume":"33","author":"F Petzke","year":"2019","unstructured":"Petzke F, Karst M, Gastmeier K, Radbruch L, Steffen E, H\u00e4user W, Ad-hoc-Kommission der Deutschen Schmerzgesellschaft \u201cCannabis in der Medizin.\u201d Position paper on medical cannabis and cannabis-based medicines in pain medicine [in German]. Schmerz. 2019;33:449\u201365. https:\/\/doi.org\/10.1007\/s00482-019-00407-2.","journal-title":"Schmerz"},{"key":"879_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s42466-020-00063-3","volume":"2","author":"T Schlereth","year":"2020","unstructured":"Schlereth T. Guideline, \u201cdiagnosis and non interventional therapy of neuropathic pain\u201d of the German Society of Neurology (deutsche Gesellschaft f\u00fcr Neurologie). Neurol Res Pract. 2020;2:16. https:\/\/doi.org\/10.1186\/s42466-020-00063-3.","journal-title":"Neurol Res Pract"},{"key":"879_CR33","unstructured":"National Institute for Health and Care Excellence Neuropathic pain in adults: pharmacological management in non-specialist settings. London: National Institute for Health and Care Excellence (UK).\u00a02020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK552848\/pdf\/Bookshelf_NBK552848.pdf. Accessed 1 June 2021."},{"key":"879_CR34","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.neurol.2020.01.361","volume":"176","author":"X Moisset","year":"2020","unstructured":"Moisset X, Bouhassira D, Avez Couturier J, Alchaar H, Conradi S, Delmotte MH, et al. Pharmacological and non-pharmacological treatments for neuropathic pain: systematic review and French recommendations. Rev Neurol (Paris). 2020;176:325\u201352. https:\/\/doi.org\/10.1016\/j.neurol.2020.01.361.","journal-title":"Rev Neurol (Paris)."},{"issue":"Suppl. 1","key":"879_CR35","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1097\/j.pain.0000000000002266","volume":"162","author":"S Haroutounian","year":"2021","unstructured":"Haroutounian S, Arendt-Nielsen L, Belton J, Blyth FM, Degenhardt L, Di Forti M, et al. International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. Pain. 2021;162(Suppl. 1):S117\u201324. https:\/\/doi.org\/10.1097\/j.pain.0000000000002266.","journal-title":"Pain"},{"key":"879_CR36","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1080\/03007995.2018.1562687","volume":"35","author":"TR T\u00f6lle","year":"2019","unstructured":"T\u00f6lle TR, Baron R, de Bock E, Junor R, Dias Barbosa C, Marshall SF, et al. painPREDICT: first interim data from the development of a new patient-reported pain questionnaire to predict treatment response using sensory symptom profiles. Curr Med Res Opin. 2019;35:1177\u201385. https:\/\/doi.org\/10.1080\/03007995.2018.1562687.","journal-title":"Curr Med Res Opin"},{"key":"879_CR37","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1097\/j.pain.000000000000213","volume":"162","author":"D Bouhassira","year":"2021","unstructured":"Bouhassira D, Branders S, Attal N, Fernandes AM, Demolle D, Barbour J, et al. Stratification of patients based on the Neuropathic Pain Symptom Inventory: development and validation of a new algorithm. Pain. 2021;162:1038\u201346. https:\/\/doi.org\/10.1097\/j.pain.000000000000213.","journal-title":"Pain"},{"key":"879_CR38","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/j.pain.0000000000002059","volume":"162","author":"M Schmelz","year":"2021","unstructured":"Schmelz M. What can we learn from the failure of quantitative sensory testing? Pain. 2021;162:663\u20134. https:\/\/doi.org\/10.1097\/j.pain.0000000000002059.","journal-title":"Pain"},{"key":"879_CR39","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/j.1532-2149.2013.00445.x","volume":"18","author":"M Serpell","year":"2014","unstructured":"Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, et al. A double-blind, randomized, placebo-controlled, parallel group study of THC\/CBD spray in peripheral neuropathic pain treatment. Eur J Pain. 2014;18:999\u20131012.","journal-title":"Eur J Pain"},{"key":"879_CR40","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/pm\/pnw134","volume":"18","author":"D Feingold","year":"2017","unstructured":"Feingold D, Goor-Aryeh I, Bril S, Delayahu Y, Lev-Ran S. Problematic use of prescription opioids and medicinal cannabis among patients suffering from chronic pain. Pain Med. 2017;18:294\u2013306. https:\/\/doi.org\/10.1093\/pm\/pnw134.","journal-title":"Pain Med"},{"key":"879_CR41","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1097\/j.pain.0000000000000548","volume":"157","author":"G Campbell","year":"2016","unstructured":"Campbell G, Bruno R, Lintzeris N, Cohen M, Nielsen S, Hall W, et al. Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: do different measures identify the same patients? Pain. 2016;157:1489\u201398. https:\/\/doi.org\/10.1097\/j.pain.0000000000000548.","journal-title":"Pain"},{"key":"879_CR42","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/s0277-9536(02)00553-1","volume":"57","author":"J Elander","year":"2003","unstructured":"Elander J, Lusher J, Bevan D, Telfer P. Pain management and symptoms of substance dependence among patients with sickle cell disease. Soc Sci Med. 2003;57:1683\u201396. https:\/\/doi.org\/10.1016\/s0277-9536(02)00553-1.","journal-title":"Soc Sci Med"},{"key":"879_CR43","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00103-019-02968-0","volume":"62","author":"G Schmidt-Wolf","year":"2019","unstructured":"Schmidt-Wolf G, Cremer-Schaeffer P. Begleiterhebung zur Anwendung von Cannabisarzneimitteln in Deutschland: Zwischenauswertung [Interim analysis of the survey accompanying insurance-covered prescriptions of cannabis-based medicines in Germany]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019;62:845\u201354. https:\/\/doi.org\/10.1007\/s00103-019-02968-0.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"Suppl. 1","key":"879_CR44","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1097\/j.pain.0000000000002000","volume":"162","author":"M Mohiuddin","year":"2021","unstructured":"Mohiuddin M, Blyth FM, Degenhardt L, Di Forti M, Eccleston C, Haroutounian S, et al. General risks of harm with cannabinoids, cannabis, and cannabis-based medicine possibly relevant to patients receiving these for pain management: an overview of systematic reviews. Pain. 2021;162(Suppl. 1):S80-96. https:\/\/doi.org\/10.1097\/j.pain.0000000000002000.","journal-title":"Pain"},{"issue":"Suppl. 1","key":"879_CR45","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1097\/j.pain.0000000000001941","volume":"162","author":"RA Moore","year":"2021","unstructured":"Moore RA, Fisher E, Finn DP, Finnerup NB, Gilron I, Haroutounian S, et al. Cannabinoids, cannabis, and cannabis-based medicines for pain management: an overview of systematic reviews. Pain. 2021;162(Suppl. 1):S67-79. https:\/\/doi.org\/10.1097\/j.pain.0000000000001941.","journal-title":"Pain"},{"key":"879_CR46","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3899\/jrheum.181120","volume":"46","author":"MA Fitzcharles","year":"2019","unstructured":"Fitzcharles MA, Niaki OZ, H\u00e4user W, Hazlewood G, Canadian Rheumatology Association. Position statement: a pragmatic approach for medical cannabis and patients with rheumatic diseases. J Rheumatolol. 2019;46:532\u20138. https:\/\/doi.org\/10.3899\/jrheum.181120.","journal-title":"J Rheumatolol"},{"key":"879_CR47","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/ejp.1736","volume":"25","author":"W H\u00e4user","year":"2021","unstructured":"H\u00e4user W, Morlion B, Vowles KE, Bannister K, Buchser E, Casale R, et al. European clinical practice recommendations on opioids for chronic noncancer pain. Part 1: role of opioids in the management of chronic noncancer pain. Eur J Pain. 2021;25:949\u201368. https:\/\/doi.org\/10.1002\/ejp.1736.","journal-title":"Eur J Pain"},{"key":"879_CR48","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/ejp.1605","volume":"24","author":"S Almog","year":"2020","unstructured":"Almog S, Aharon-Peretz J, Vulfsons S, Ogintz M, Abalia H, Lupo T, et al. The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: a randomized, double-blinded, placebo-controlled trial. Eur J Pain. 2020;24:1505\u201316. https:\/\/doi.org\/10.1002\/ejp.1605.","journal-title":"Eur J Pain"},{"key":"879_CR49","unstructured":"Office of Medicinal Cannabis. Patient\u2019s guide medicinale cannabis. Available from: https:\/\/english.cannabisbureau.nl\/medicinal-cannabis\/documents\/circulars\/2018\/02\/20\/patients-guide-medicinal-cannabis. Accessed 21 June 2021."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00879-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00879-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00879-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T11:50:59Z","timestamp":1641383459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00879-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,21]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["879"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00879-w","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,21]]},"assertion":[{"value":"4 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"WH, FP and MAF have no financial conflicts of interest to declare. WH is the head of EFIC\u2019s Task Force of a position paper on CbMs and MC for chronic pain and a member of the Task Force of the German Pain Society on the same topic. FP is the head of the Task Force of the German Pain Society of a position paper on CbMs and MC for chronic pain. MAF is the head of a Task Force of the Canadian Association of Rheumatology of a position paper on MC for rheumatic diseases. TT has received honoraria for consultancies, travel grants and speaking fees for AOP Orphan, Almiral Hermal, Bionest Partners, Benkitt Renkiser, Gr\u00fcnenthal, Hexal, Indivior, Kaia Health, Lilly, Medscape, Mundipharma, MSD, Novartis, Pfizer, Recordati Pharma, Sanofi-Aventis and TAD Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors participated in writing the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}